| Ytd | -27.97% | |
| 1y | -54.86% |
| Open | 18.36 | Prev Close | 18.86 | Low | 18.36 | High | 19.00 | Mkt Cap | 1.74B |
| Vol | 8.99K | Avg Vol | 19.05K | EPS | N/A | P/E | N/A | Forward P/E | -15.88 |
| Beta | 0.09 | Short Ratio | 0.08 | Inst. Own | 0.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-25 | 50-d Avg | 19.33 | 200-d Avg | 26.52 | 1yr Est | 47.56 |
AAPG News
The consensus price target hints at a 152.2% upside potential for Ascentage Pharma Group Internation
U.S. stock futures down, Nasdaq 100 futures drop over 1%. ON Semi to acquire Synaptics, ON shares fa
B. Riley Securities analyst Mayank Mamtani initiates coverage on Ascentage Pharma Group (NASDAQ:A
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result
U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benc
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, I
JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech&#
US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025